JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Vaxart Inc

Закрыт

0.32

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

Макс.

Ключевые показатели

By Trading Economics

Доход

605K

-15M

Продажи

19M

40M

Рентабельность продаж

-37.72

Сотрудники

105

EBITDA

155K

-12M

Дивиденды

By Dow Jones

Следующий отчет о доходах

12 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.4M

81M

Предыдущая цена открытия

0.32

Предыдущая цена закрытия

0.32

Техническая оценка

By Trading Central

Уверенность

Bearish Evidence

Vaxart Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

26 окт. 2025 г., 23:52 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

26 окт. 2025 г., 23:52 UTC

Обсуждения рынка

Nikkei May Rise on Weaker Yen -- Market Talk

26 окт. 2025 г., 23:46 UTC

Обсуждения рынка

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 окт. 2025 г., 23:41 UTC

Обсуждения рынка

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 окт. 2025 г., 23:34 UTC

Отчет

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 окт. 2025 г., 23:32 UTC

Отчет

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 окт. 2025 г., 23:30 UTC

Отчет

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 окт. 2025 г., 22:16 UTC

Отчет

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 окт. 2025 г., 21:33 UTC

Приобретения, слияния, поглощения

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 окт. 2025 г., 19:29 UTC

Приобретения, слияния, поглощения

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Vaxart Inc Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

0.4007 / 0.4252Поддержка и Сопротивление

Краткосрочная

Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
help-icon Live chat